|
US5385946A
(en)
*
|
1986-07-10 |
1995-01-31 |
State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University And The University Of Oregon |
Method for treating hypertension with disubstituted granidine compounds
|
|
US5190976A
(en)
*
|
1986-07-10 |
1993-03-02 |
State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University And University Of Oregon |
N,N'-disubstituted guanidines and their use as excitatory amino acid antagonists
|
|
US5312840A
(en)
*
|
1986-07-10 |
1994-05-17 |
State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education |
Substituted guanidines having high binding to the sigma receptor and the use thereof
|
|
US5336689A
(en)
*
|
1990-03-02 |
1994-08-09 |
State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University And The University Of Oregon |
Tri- and tetra-substituted guanidines and their use as excitatory amino acid antagonists
|
|
US5262568A
(en)
*
|
1990-03-02 |
1993-11-16 |
State Of Oregon |
Tri- and tetra-substituted guanidines and their use as excitatory amino acid antagonists
|
|
IE910719A1
(en)
*
|
1990-03-02 |
1991-09-11 |
Oregon State |
Tri- and tetra-substituted guanidines and their use as¹excitatory amino acid and antagonists
|
|
JPH05508836A
(ja)
*
|
1990-05-25 |
1993-12-09 |
オレゴン州 |
シグマ受容体に対して高い結合性を有する置換グアニジンおよびその使用
|
|
US5847006A
(en)
*
|
1991-02-08 |
1998-12-08 |
Cambridge Neuroscience, Inc. |
Therapeutic guanidines
|
|
US5741661A
(en)
*
|
1991-02-08 |
1998-04-21 |
Cambridge Neuroscience, Inc. |
Substituted guanidines and derivatives thereof as modulators of neurotransmitter release and novel methodology for identifying neurotransmitter release blockers
|
|
EP0940139B1
(en)
*
|
1991-02-08 |
2005-02-02 |
Scion Pharmaceuticals, Inc. |
Substituted guanidines and derivatives thereof as modulators of neurotransmitter release and novel methodology for identifying neurotransmitter release blockers
|
|
DK68592D0
(da)
*
|
1992-05-25 |
1992-05-25 |
Novo Nordisk As |
Celle
|
|
US5321012A
(en)
*
|
1993-01-28 |
1994-06-14 |
Virginia Commonwealth University Medical College |
Inhibiting the development of tolerance to and/or dependence on a narcotic addictive substance
|
|
USRE39300E1
(en)
|
1993-01-28 |
2006-09-19 |
Virginia Commonwealth University Medical College Of Virginia |
Inhibiting the development of tolerance to and/or dependence on an addictive substance
|
|
JP3610368B2
(ja)
*
|
1993-05-27 |
2005-01-12 |
セネス リミティド |
治療用置換グアニジン
|
|
WO1995014461A1
(en)
*
|
1993-11-23 |
1995-06-01 |
Cambridge Neuroscience, Inc. |
Therapeutic substituted guanidines
|
|
AU1912595A
(en)
*
|
1994-02-03 |
1995-08-21 |
Cambridge Neuroscience, Inc. |
Therapeutic guanidines
|
|
US7351743B1
(en)
|
1994-02-03 |
2008-04-01 |
Wyeth |
Therapeutic guanidines
|
|
US6787569B1
(en)
|
1994-02-03 |
2004-09-07 |
Cambridge Neuroscience, Inc. |
Therapeutic guanidines
|
|
US6143791A
(en)
*
|
1994-02-03 |
2000-11-07 |
Cambridge Neuroscience, Inc. |
Therapeutic guanidines
|
|
US5733932A
(en)
*
|
1995-01-06 |
1998-03-31 |
The Picower Institute For Medical Research |
Compounds and methods of use to derivatize neighboring lysine residues in proteins under physiological conditions
|
|
US6011021A
(en)
*
|
1996-06-17 |
2000-01-04 |
Guilford Pharmaceuticals Inc. |
Methods of cancer treatment using naaladase inhibitors
|
|
US5935606A
(en)
*
|
1995-07-31 |
1999-08-10 |
Sagen; Jaqueline |
Reversing excitotoxic CNS damage by cellular implantation
|
|
US6025355A
(en)
|
1997-05-19 |
2000-02-15 |
Cambridge Neuroscience, Inc. |
Pharmaceutically active compounds and methods of use
|
|
DE19621038A1
(de)
|
1996-05-24 |
1997-11-27 |
Boehringer Ingelheim Kg |
Aminoguanidine, Verfahren zu ihrer Herstellung und Arzneimittel, die diese Verbindungen enthalten
|
|
US5795877A
(en)
*
|
1996-12-31 |
1998-08-18 |
Guilford Pharmaceuticals Inc. |
Inhibitors of NAALADase enzyme activity
|
|
US6025345A
(en)
*
|
1996-06-17 |
2000-02-15 |
Guilford Pharmaceuticals Inc. |
Inhibitors of NAALADase enzyme activity
|
|
US6054444A
(en)
*
|
1997-04-24 |
2000-04-25 |
Guilford Pharmaceuticals Inc. |
Phosphonic acid derivatives
|
|
US6384022B1
(en)
|
1996-06-17 |
2002-05-07 |
Guilford Pharmaceuticals Inc. |
Prodrugs of NAALAdase inhibitors
|
|
US6046180A
(en)
*
|
1996-06-17 |
2000-04-04 |
Guilford Pharmaceuticals Inc. |
NAALADase inhibitors
|
|
US5672592A
(en)
*
|
1996-06-17 |
1997-09-30 |
Guilford Pharmaceuticals Inc. |
Certain phosphonomethyl-pentanedioic acid derivatives thereof
|
|
US5863536A
(en)
*
|
1996-12-31 |
1999-01-26 |
Guilford Pharmaceuticals Inc. |
Phosphoramidate derivatives
|
|
US6025344A
(en)
|
1996-06-17 |
2000-02-15 |
Guilford Pharmaceuticals Inc. |
Certain dioic acid derivatives useful as NAALADase inhibitors
|
|
US6071965A
(en)
*
|
1996-06-17 |
2000-06-06 |
Guilford Pharmaceuticals Inc. |
Phosphinic alkanoic acid derivatives
|
|
JP2002515040A
(ja)
|
1996-06-17 |
2002-05-21 |
ギルフォード・ファーマシューティカルズ・インコーポレイテッド |
Naaladアーゼ阻害剤を用いる癌治療方法
|
|
US5902817A
(en)
*
|
1997-04-09 |
1999-05-11 |
Guilford Pharmaceuticals Inc. |
Certain sulfoxide and sulfone derivatives
|
|
US6242198B1
(en)
|
1996-07-25 |
2001-06-05 |
Cambridge Neuroscience, Inc. |
Methods of treatment of eye trauma and disorders
|
|
US6756389B2
(en)
*
|
1996-08-09 |
2004-06-29 |
Cambridge Neuroscience, Inc. |
Pharmaceutically active compounds and methods of use
|
|
US5962521A
(en)
*
|
1997-04-04 |
1999-10-05 |
Guilford Pharmaceuticals Inc. |
Hydroxamic acid derivatives
|
|
WO1998036743A1
(en)
*
|
1997-02-21 |
1998-08-27 |
Cypros Pharmaceutical Corporation |
Neuroprotective poly-guanidino compounds which block presynaptic n and p/q calcium channels
|
|
WO1998041223A1
(en)
*
|
1997-03-20 |
1998-09-24 |
The Regents Of The University Of California |
N-methyl-d-aspartate receptor channel blockers and method for identifying such
|
|
US5981209A
(en)
*
|
1997-12-04 |
1999-11-09 |
Guilford Pharmaceuticals Inc. |
Use of NAALADase activity to identify prostate cancer and benign prostatic hyperplasia
|
|
US6028216A
(en)
*
|
1997-12-31 |
2000-02-22 |
Guilford Pharmaceuticals Inc. |
Asymmetric syntheses and intermediates for preparing enantiomer-enriched hydroxyphosphinyl derivatives
|
|
US6121252A
(en)
*
|
1998-03-30 |
2000-09-19 |
Guilford Pharmaceuticals Inc. |
Phosphinic acid derivatives
|
|
US6395718B1
(en)
|
1998-07-06 |
2002-05-28 |
Guilford Pharmaceuticals Inc. |
Pharmaceutical compositions and methods of inhibiting angiogenesis using naaladase inhibitors
|
|
US6265609B1
(en)
|
1998-07-06 |
2001-07-24 |
Guilford Pharmaceuticals Inc. |
Thio-substituted pentanedioic acid derivatives
|
|
MXPA01000144A
(es)
|
1998-07-06 |
2002-10-17 |
Guilford Pharm Inc |
Inhibidores de naaladasa utiles como composiciones y compuestos farmaceuticos.
|
|
US6444657B1
(en)
|
1998-12-31 |
2002-09-03 |
Guilford Pharmaceuticals Inc. |
Methods for treating certain diseases using naaladase inhibitors
|
|
WO2000072800A2
(en)
*
|
1999-05-28 |
2000-12-07 |
Smithkline Beecham Corporation |
Il-8 receptor antagonists
|
|
US6875759B1
(en)
|
1999-07-21 |
2005-04-05 |
Kadmus Pharmaceuticals |
Substituted guanidines and the use thereof
|
|
US6313159B1
(en)
|
1999-08-20 |
2001-11-06 |
Guilford Pharmaceuticals Inc. |
Metabotropic glutamate receptor ligand derivatives as naaladase inhibitors
|
|
JP2005506292A
(ja)
*
|
2001-03-08 |
2005-03-03 |
エモリー ユニバーシティ |
pHに依存するNMDAレセプターアンタゴニスト
|
|
WO2003078448A1
(en)
|
2002-03-13 |
2003-09-25 |
Signum Biosciences, Inc. |
Modulation of protein methylation and phosphoprotein phosphate
|
|
US7923041B2
(en)
|
2005-02-03 |
2011-04-12 |
Signum Biosciences, Inc. |
Compositions and methods for enhancing cognitive function
|
|
WO2006084033A1
(en)
*
|
2005-02-03 |
2006-08-10 |
Signum Biosciences, Inc. |
Compositions and methods for enhancing cognitive function
|
|
WO2007047978A2
(en)
|
2005-10-21 |
2007-04-26 |
Braincells, Inc. |
Modulation of neurogenesis by pde inhibition
|
|
EP2314289A1
(en)
|
2005-10-31 |
2011-04-27 |
Braincells, Inc. |
Gaba receptor mediated modulation of neurogenesis
|
|
CA2643199A1
(en)
*
|
2006-03-08 |
2007-09-13 |
Braincells, Inc. |
Modulation of neurogenesis by nootropic agents
|
|
US20100216734A1
(en)
|
2006-03-08 |
2010-08-26 |
Braincells, Inc. |
Modulation of neurogenesis by nootropic agents
|
|
EP2021000A2
(en)
|
2006-05-09 |
2009-02-11 |
Braincells, Inc. |
Neurogenesis by modulating angiotensin
|
|
US7678808B2
(en)
|
2006-05-09 |
2010-03-16 |
Braincells, Inc. |
5 HT receptor mediated neurogenesis
|
|
US20100009983A1
(en)
*
|
2006-05-09 |
2010-01-14 |
Braincells, Inc. |
5 ht receptor mediated neurogenesis
|
|
WO2008030651A1
(en)
|
2006-09-08 |
2008-03-13 |
Braincells, Inc. |
Combinations containing a 4-acylaminopyridine derivative
|
|
US20100184806A1
(en)
|
2006-09-19 |
2010-07-22 |
Braincells, Inc. |
Modulation of neurogenesis by ppar agents
|
|
EP2066355A2
(en)
*
|
2006-09-19 |
2009-06-10 |
Braincells, Inc. |
Combination comprising a peroxisome proliferator activated receptor agent and a second neurogenic agent for treating a nervous system disorder, increasing neurodifferentiation and increasing neurogenesis
|
|
KR20100045983A
(ko)
|
2007-06-29 |
2010-05-04 |
에모리 유니버시티 |
신경보호를 위한 nmda 수용체 길항물질
|
|
CN102014897B
(zh)
|
2008-04-21 |
2015-08-05 |
西格纳姆生物科学公司 |
化合物、组合物和其制备方法
|
|
WO2010048164A2
(en)
*
|
2008-10-20 |
2010-04-29 |
University Of South Florida |
N,n'-di-p-bromophenyl guanidine treatment for stroke at delayed timepoints
|
|
US20100216805A1
(en)
|
2009-02-25 |
2010-08-26 |
Braincells, Inc. |
Modulation of neurogenesis using d-cycloserine combinations
|
|
RU2612533C2
(ru)
*
|
2011-10-11 |
2017-03-09 |
Универсидад Насьональ Де Килмес |
Производные фенилгуанидина
|